

# Investigation of genetic variations of *IL6* and *IL6R* as potential prognostic and pharmacogenetics biomarkers: implications for COVID19 and neuroinflammatory disorders.

**Claudia Strafella** (✉ [claudia.strafella@gmail.com](mailto:claudia.strafella@gmail.com))

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome; Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

**Valerio Caputo**

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome; Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

**Andrea Termine**

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy

**Shila Barati**

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy

**Carlo Caltagirone**

Department of Clinical and Behavioral Neurology, IRCCS Fondazione Santa Lucia, Rome, Italy

**Emiliano Giardina**

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome; UILDM Lazio ONLUS Foundation, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

**Raffaella Cascella**

Genomic Medicine Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy; Department of Biomedical Sciences, Catholic University Our Lady of Good Counsel, Tirana, Albania

---

## Research Article

**Keywords:** Biomarkers, IL-6, IL6R, SARS-Cov-2, COVID19, neurodegenerative disorders, genetic variants, precision medicine

**Posted Date:** September 16th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-77342/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Life on December 16th, 2020. See the published version at <https://doi.org/10.3390/life10120351>.

## Abstract

In the present study, we investigated the distribution of genetic variations in *IL6* and *IL6R* genes, which may be employed as prognostic and pharmacogenetic biomarkers for COVID-19 and neurodegenerative diseases. The study was performed on 271 samples representative of the Italian general population and identified seven variants (rs140764737, rs142164099, rs2069849, rs142759801, rs190436077, rs148171375, rs13306435) in *IL6* and five variants (rs2228144, rs2229237, rs2228145, rs28730735, rs143810642) within *IL6R*, respectively. These variants have been predicted to affect the expression and binding ability of IL6 and IL6R. The Ingenuity Pathway Analysis (IPA) showed that IL6 and IL6R appeared to be implicated in several pathogenetic mechanisms associated with COVID19 severity and mortality as well as with neurodegenerative diseases mediated by neuroinflammation. Thus, the availability of IL6-IL6R-related biomarkers for COVID19 disease may be helpful to counteract harmful complications and prevent multi-organ failure. At the same time, IL6-IL6R-related biomarkers could also be useful for assessing the susceptibility and progression of neuroinflammatory disorders and undertake the most suitable treatment strategies to improve patients' prognosis and quality of life. In conclusion, this study showed how IL6 pleiotropic activity could be exploited to meet different clinical needs and realize precision medicine protocols for chronic, age-related and modern public health emergencies.

## Introduction

The identification of biological markers (i.e. biomarkers) of disease detectable in several biological fluids and tissues represents the key milestone for the implementation of precision medicine protocols into the clinical practice [1-5]. The need of clinically useful biomarkers and precision medicine strategies became even more important with the recent outbreak of the novel pathogenic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) and the resulting Coronavirus Infectious Disease (COVID19) pandemics [6-7]. However, COVID19 is just the most recent challenges for the healthcare system, which has also to tackle with a growing aging population and the diverse pathological conditions affecting the elderly, such as neurodegenerative disorders. Interestingly, neurodegenerative disorders and viral infections pathologies share several molecular signatures, which, altogether, indicate the dysfunction of local and peripheral immune system response as a common etiopathogenetic mechanism [8-10]. In this context, the availability of specific biomarkers could be extremely helpful to identify at-risk individuals, select the most suitable therapy and counteract the progression and mortality of such public health emergencies. Two of the most promising candidate biomarkers for both COVID19 and neurodegenerative disorders are Interleukin-6 (IL6) and its receptor (IL6R). IL6 consists of a four-helix bundle conformation and exerts its functions by binding the Interlukin-6 Receptor (IL6R) [11]. IL6R can be either membrane-bound (classical signaling) on the extracellular surface of immune, epithelial and liver cells or it can be circulating in soluble form (trans-signaling pathway) and act as IL6 agonist [12-13]. The IL6-IL6R complex interacts with the glycoprotein 130 (gp130) membrane receptor, which, in turn, triggers downstream intracellular signaling pathways (Figure 1) mainly involved in the immuno-inflammatory response [11,13].

Genetic variants in *IL6* (7p15.3) and *IL6R* (1q21.3) genes have been supposed to affect the binding ability, expression levels and biological functions of IL6-IL6R complex, contributing thereby to the onset and progression of severe infectious, autoimmune and neuroinflammatory/neurodegenerative diseases, including COVID19, Hepatitis B infection, Rheumatoid Arthritis (RA), Cardiovascular Disorders (CVD), Multiple Sclerosis (MS), Alzheimer Disease (AD) and Parkinson Disease (PD) [14-17]. Indeed, a number of studies identified variants located in the regulatory regions of IL6 and IL6R as genetic determinants of high IL6 circulating levels in serum and tissues that have been proposed to affect the risk and progression of many different disease states (especially COVID19, CVD and AD) [16-18]. In the present study, we investigated the distribution of Copy Number Variations (CNVs) and genetic variants located within the coding sequences of *IL6* and *IL6R* genes, which may be employed as prognostic and drug response (pharmacogenetic) biomarkers for COVID-19 and neuroinflammatory diseases. We decided to focus the attention on these pathologies because they both represent current public health issues and the identification of biomarkers within *IL6* and *IL6R* could provide therapeutic strategies relevant to both pathological conditions.

## Materials And Methods

The study was performed on a cohort of 271 DNA samples representative of the Italian general population. The study cohort was composed of 100 samples analyzed by array Comparative Genomic Hybridization (aCGH) for assessing the presence of structural genomic variations and 171 samples utilized for identifying common and rare Single Nucleotide Variants (SNVs) located in the coding or splice site regions of the genome. Genetic data were partially obtained from aCGH and Whole Exome Sequencing (WES) data available at the Genomic Medicine Laboratory of IRCCS Santa Lucia Foundation and partially retrieved from Ensembl [19-21]. The use of laboratory data for research purposes was approved by the Ethics Committee of IRCCS Santa Lucia Foundation of Rome (CE/PROG.650 approved on 01/03/2018) and by the signed informed consent provided by the individuals subjected to genetic testing at our laboratory.

The CNV analysis was performed by Chromosome Analysis Suite (ChAS) 3.1 (Affymetrix, Santa Clara, CA, USA) using the Cytoscan750k\_Array Single Sample analysis: NA33\_hg19 as reference file and an average resolution of 100 Kb. Concerning SNVs, Ensembl [19], 1000Genomes [20] and GnomAD [21] databases were utilized to extract the frequency data of the exonic variants of interest. In particular, 22 variants located within IL6 and 37 variants within IL6R were selected. Successively, the presence and the frequency distribution of the selected variants have been evaluated in the cohort of Italian samples. For WES results, a coverage of 20X was considered for the analysis of IL6 and IL6R sequence. The Variant Caller Files (VCF) obtained by WES analysis were firstly scanned with vcfR and then subjected to “genomic variants filtering by deep learning models in NGS” (GARFIELD-NGS) analysis. In particular, vcfR is a package that enables to visualize, manipulate and perform the quality control of VCF data [22]. GARFIELD-NGS is an informatics tool, which relies on deep learning models to dissect false and true variants in exome sequencing experiments [23].

Successively, the identified variants were subjected to bioinformatic predictive analysis in order to assess their potential impact on protein expression and function. In particular, VarSite and Human Splicing Finder (HSF) were interrogated. VarSite analyzes and predicts the effect of amino acid changes on the protein structure [24]. HSF evaluates the effects of variants on the splicing mechanisms [25]. Moreover, Uniprot annotation database was utilized to retrieve the topological and functional domains organization of proteins [26]. Moreover, Ingenuity Pathway Analysis (IPA, Qiagen) software application was performed in order to place IL6 and IL6R into their biological context and postulate their possible association with COVID19 severity and neuroinflammatory disorders and their potential use as druggable targets. IPA is an all-in-one web-based software application that allow the analysis and integration of different kinds of genetic data, facilitating their interpretation, the identification of specific targets or candidate biomarkers and placing them in the context of larger biological or chemical systems. The software is backed by the Ingenuity Knowledge Base, which consists of highly structured, detail-rich biological and chemical findings. The entire analytical workflow of the study has been illustrated in Figure 2.

## Results And Discussion

The present study investigated the distribution of CNVs and SNVs located within the coding sequences of IL6 and IL6R genes, with the aim of identifying candidate prognostic and pharmacogenetic biomarkers for COVID-19 and neuroinflammatory diseases. The analysis of CNVs did not report any significant variation in our study cohort ruling out that frequent copy number variations could potentially impact IL6 and IL6R expression. Concerning SNVs instead, 22 variants located within IL6 and 37 variants within IL6R were selected and investigated in the cohort of Italian samples. As a result, seven variants located within IL6 and five variants within IL6R were identified, respectively (Table 1). Among the variants of IL6, three were synonymous (rs140764737, C/T; rs142164099, G/A, rs2069849, C/T) and four missense (rs142759801, C/A; rs190436077, G/C; rs148171375, A/T and rs13306435, T/A). These variants appeared to be rare in the Italian cohort, with a Minor Allele Frequency (MAF) ranging from 0.009 and 0.003 (Table 1).

**Table 1.** Exonic variants located within IL6 and IL6R found in the cohort of 171 samples representative of the Italian general population. The table reports the gene and genomic location of each variant according to GRCh37 release, SNP, nucleotide and protein coding, allele counts (frequencies) in the study cohort, exonic location and the impact of variants on structure (Varsite) and splicing (HSF). Ex: Exon; AA: amino acid.

Gene	Genomic Location	SNP	Nucleotide Coding	Allele counts (frequencies)	Ex	Protein Coding	Structural impact of AA change (Varsite)	Impact on splicing (HSF)
<b>IL6 (7p15.3)</b>	7:22767134	rs142759801	c.91C>A	C: 341 (0.997) A: 1 (0.003)	2	p.Pro31Thr	low impact on protein structure	alteration of an ESE site
	7:22767226	rs140764737	c.183C>T	C: 341 (0.997) T: 1 (0.003)	2	p.Leu61=	NA	alteration of an ESE site, creation of an ESS site
	7:22768336	rs190436077	c.235G>C	G: 341 (0.997) C: 1 (0.003)	3	p.Glu79Gln	potential impact on protein structure	alteration of an ESE site
	7:22768350	rs142164099	c.249G>A	G: 341 (0.997) A: 1 (0.003)	3	p.Glu83=	NA	no predicted impact
	7:22769154	rs148171375	c.346A>T	A: 341 (0.997) T: 1 (0.003)	4	p.Ile116Phe	low impact on protein structure	no predicted impact
	7:22771039	rs13306435	c.486T>A	T: 339 (0.991) A: 3 (0.009)	5	p.Asp162Glu	potential impact on protein structure	no predicted impact
	7:22771156	rs2069849	c.603C>T	C: 339 (0.991) A: 3 (0.009)	5	p.Phe201=	NA	no predicted impact
<b>IL6R (1q21.3)</b>	1:154401679	rs2228144	c.93G>A	G: 281 (0.822) A: 61 (0.178)	2	p.Ala31=	NA	no predicted impact
	1:154401796	rs2229237	c.210C>T	C: 338 (0.988) T: 4 (0.012)	2	p.His70=	NA	alteration of an ESE site, creation of an ESS site
	1:154426970	rs2228145	c.1073A>C	A: 230 (0.673) C: 112 (0.327)	9	p.Asp358Ala	potential impact on protein structure	alteration of an ESE site, creation of an ESS site
	1:154427032	rs28730735	c.1135C>T	C: 340 (0.994) T: 2 (0.006)	9	p.Leu379Phe	low impact on protein structure	alteration of an ESE site, creation

							of an ESS site
1:154437719	rs143810642	c.1270C>T	C: 340 (0.994) T: 2 (0.006)	10	p.Leu424Phe	low impact on protein structure	alteration of an ESE site, creation of an ESS site

Concerning the synonymous variants, only rs140764737 has been predicted to impact on the regulation of splicing mechanisms. According to HSF, the T variant allele may disrupt an Exonic Splicing Enhancer (ESE) site and create a new Exonic Splicing Silencer (ESS). The analyses conducted on the missense variants unveiled that rs142759801 (C/A) may affect IL6 expression and function through the impairment of canonical splicing mechanisms. In fact, HSF interrogation reported a potential alteration of an ESE site. VarSite did not report any effect on protein structure. Furthermore, the bioinformatic predictive analysis suggested that rs190436077 and rs13306435 may impact on protein structure because of their amino acid substitution, whereas rs148171375 was not predicted to affect protein function, structure and splicing activity. In fact, the rs190436077 causes a Glutamate (with a negatively charged side chain) to Glutamine (carrying a neutral side chain) change at the 79th amino acid and it has also been predicted to disrupt an ESE site. Moreover, it falls within the loop connecting the first two helical structures of the protein, which contributes to the formation of the binding site for IL6/IL6R complex to gp130 (23). The rs190436077 may therefore be experimentally investigated to verify its potential role on the alteration of IL6 binding ability and could be also evaluated for potential effects on the affinity with IL6 drugs, which may cause an altered drug response or effectiveness. Concerning the variants located within IL6R, two synonymous (rs2228144, G/A and rs2229237, C/T) and three missense variants (rs2228145, A/C; rs28730735, C/T and rs143810642, C/T) were detected in the Italian cohort. These variants showed variable frequency distributions, with the rs2228144 (MAF: 0.178) and rs2228145 (MAF: 0.327) being the most frequently observed (Table 1). Concerning the synonymous variants, the bioinformatic analysis supported an effect on the splicing mechanisms for the rs2229237 variant, which was predicted to activate a cryptic acceptor site and alter the regulatory splicing sequences (Table 1). All the missense variants were predicted to alter ESE sites and/or create new ESS sites, whereas the rs2228145 was also predicted to impact on the protein function due to the amino acid substitution from an Aspartate (Asp, with a negatively charged side chain) to Alanine (Ala, with an aliphatic side chain) at the 358th residue. Interestingly, this amino-acid variant is located within the extracellular domain of the receptor, which is fundamental for IL6R interaction with extracellular ligands. Therefore, the variant may alter the domain conformation, potentially interfering with IL6 recognition. Indeed, the C allele of rs2228145 is strongly associated with increased levels of soluble IL6R in blood, serum and Cerebrospinal Fluid (CSF) [11, 27]. This finding may be explained by the fact that the Ala residue makes the conformation at this site more susceptible to the cleavage, leading to increased levels of soluble IL6R [11].

Over the investigation of coding variants in IL6 and IL6R genes, we performed a “Disease and Function” analysis on IPA to visualize the pathophysiological pathways in which IL6 and IL6R may be implicated, how they could affect the severity/progression of COVID19 and neuroinflammatory disease and their possible use as druggable targets for these conditions. According to this analysis, IL6 and IL6R appeared to be implicated in several pathogenetic mechanisms associated with COVID19 severity and mortality, especially affecting lungs, liver, heart and nervous system (Figure 3).

Notably, lung is the most affected organ by SARS-Cov-2, whose infection triggers acute immuno-inflammatory responses culminating in decreased oxygen uptake, lung injury and severe pneumonia [28]. Moreover, acute cardiac injury (arrhythmias, myocardial infarction and heart failure) and abnormal blood clotting have been reported as complications of SARS-Cov-2 infection in approximately 20-30% and 38% of COVID19 patients, respectively [28-29]. Cardiac and blood vessels involvement can result by direct and indirect mechanisms, including viral infiltration into myocardial tissue (causing cardiomyocyte death

and inflammation), stress induced by respiratory failure and hypoxemia and inflammation due to severe systemic hyperinflammation [29]. In 14-53% cases, abnormal levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, lymphopenia have been associated with hepatic dysfunction and liver injury [30-31]. These alterations may be either a consequence of direct viral invasion or may be due to drugs hepatotoxicity and immune system overdrive. In addition, 14-36% of severe COVID-19 patients reported neurological symptoms, such as taste and smell impairment, dizziness, seizures, impaired consciousness, encephalitis, stroke [32-33]. Even in this case, neurological symptoms could depend from brain viral infection or from the systemic hyperinflammation and abnormal blood clotting. In addition, the "Disease and Function" analysis reported that IL6 and IL6R were implicated in damage of synapses, microglia proliferation, astrocytes swelling and severe dementia in AD (namely, clinical dementia rating score 3 Alzheimer's disease) (Figure 3). These data, together with the evidence of association between high IL6 levels and neuroinflammation [11], advocate for a role of IL6 and IL6R as molecular contributors to AD progression and designate them as candidate druggable targets for AD and other neurodegenerative diseases mediated by neuroinflammation.

## Conclusions

Considering the above-presented data, we encourage similar studies on other populations to verify the existence of population-specific genomic profiles, which could contribute to the differential susceptibility and progression of COVID19 and/or neuroinflammatory diseases as well as to the variable drug response. It is important to remark that IL6 and IL6R are excellent targets for immuno-modulatory therapies because of their pleiotropic effects in several tissues (liver, brain, bone, lung, skeletal muscle, heart) and biological fluids (blood, serum/plasma, urine). In fact, several drugs (sirukumab, clazakizumab, siltuximab and olokizumab) targeting IL6 have been designed and are currently approved or under investigation for treating RA, Chron's disease, depression, Lupus nephritis and Castleman disease. Concerning IL6R-targeting drugs, Sarilumab is currently indicated for moderate to severe active RA, whereas Tocilizumab is utilized in the treatment of moderate to severe RA, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome. In addition, Tocilizumab is currently under investigation as treatment option for patients affected with severe COVID-19 [34-35]. Given this data, the availability of IL6-IL6R-related biomarkers for COVID19 disease may be helpful to counteract or timely treat harmful complications and prevent multi-organ failure. At the same time, IL6-IL6R-related biomarkers could also be useful for assessing the susceptibility and progression of neuroinflammatory disorders and undertake the most suitable treatment strategies in order to improve patients' prognosis and quality of life. In conclusion, this study showed how IL6 pleiotropic activity could be exploited to meet different clinical needs and achieve the realization of precision medicine protocols for chronic, age-related and modern public health emergencies.

## Declarations

### Data Availability

The authors declare that all data supporting the findings of the study are available in this article or upon reasonable request to the corresponding author.

### Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

### Funding Statement

This research received no external funding.

## References

- [1] Bravo-Merodio, L.; Williams J.A.; Gkoutos G.V.; Acharjee, A. -Omics biomarker identification pipeline for translational medicine. *J Transl Med* 2019, 17, 155. Doi: 10.1186/s12967-019-1912-5.
- [2] Cascella, R.; Strafella, C.; Longo, G.; Maccarone, M.; Borgiani, P.; Sangiuolo, F.; Novelli, G.; Giardina, E. Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis. *Pharmacogenomics* 2016; 17, 943–951. Doi: 10.2217/pgs.16.20.
- [3] Stocchi, L.; Cascella, R.; Zampatti, S.; Pirazzoli, A.; Novelli, G.; Giardina, E. The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods. *Curr Genomics* 2012, 13, 314-320. Doi: 10.2174/138920212800793311.
- [4] Docampo, E.; Giardina, E.; Riveira-Muñoz, E.; de Cid, R.; Escaramís, G.; Perricone, C.; Fernández-Sueiro, J.L., Maymó, J.; González-Gay, M.A.; Blanco, F.J.; Hüffmeier, U.; Lisbona, M.P.; Martín, J.; Carracedo, A.; Reis, A.; Rabionet, R.; Novelli, G.; Estivill, X. Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: a study in Spanish and Italian populations and meta-analysis. *Arthritis Rheum* 2011, 63, 1860-1865. Doi: 10.1002/art.30340.
- [5] Giardina, E.; Capon, F.; De Rosa, M.C.; Mango, R.; Zambruno, R.; Orecchia, A.; Chimenti, S.; Giardina, B.; Novelli, G. Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus. *Ann. Hum. Genet.* 2004, 68, 639-645. Doi: 10.1046/j.1529-8817.2004.00118.x.
- [6] Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 - A systematic review. *Life Sci* 2020, 254, 117788. Doi: 10.1016/j.lfs.2020.117788.
- [7] Strafella, C.; Caputo, V.; Termine, A.; Barati, S.; Gambardella, S.; Borgiani, P.; Caltagirone, C.; Novelli, G.; Giardina, E.; Cascella, R. Analysis of ACE2 Genetic Variability among Populations Highlights a Possible Link with COVID-19-Related Neurological Complications. *Genes* 2020, 11, 741. Doi: 10.3390/genes11070741.
- [8] Costa Sa AC, Madsen H, Brown JR. Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. *Sci Rep* 2019, 9, 8795. Doi:10.1038/s41598-019-45129-8.
- [9] Sochocka M, Zwolińska K, Leszek J. The Infectious Etiology of Alzheimer's Disease. *Curr Neuropharmacol* 2017, 15, 996-1009. Doi: 10.2174/1570159X15666170313122937.
- [10] Strafella, C.; Caputo, V.; Galota, M.R.; Zampatti, S.; Marella, G.; Mauriello, S.; Cascella, R.; Giardina, E. Application of Precision Medicine in Neurodegenerative Diseases. *Front Neurol* 2018, 9, 701. Doi: 10.3389/fneur.2018.00701.
- [11] Garbers, C.; Heink, S.; Korn, T.; Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. *Nat Rev Drug Discov* 2018, 17, 395-412. Doi: 10.1038/nrd.2018.45.
- [12] Murakami, M.; Kamimura, D.; Hirano, T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. *Immunity* 2019, 50, 812-831. Doi: 10.1016/j.immuni.2019.03.027.
- [13] Salvi, R.; Patankar, P. Emerging pharmacotherapies for COVID-19. *Biomed Pharmacother* 2020, 128, 110267. Doi:10.1016/j.biopha.2020.110267.
- [14] Ulhaq, Z.S., Soraya, G.V. Interleukin-6 as a potential biomarker of COVID-19 progression. *Med Mal Infect* 2020, 50, 382-383. Doi:10.1016/j.medmal.2020.04.002.
- [15] Redenšek, S.; Flisar, D.; Kojović, M.; Kramberger, M.G.; Georgiev, D.; Pirtošek, Z.; Trošt, M.; Dolžan, V. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease. *J Neuroinflammation* 2019, 16, 50. Doi:10.1186/s12974-019-1439-y.

- [16] Mun, M.J.; Kim, J.H.; Choi, J.Y.; Jang, W.C. Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis. *Meta Gene*. 2016, 8, 1-10. Doi:10.1016/j.mgene.2016.01.001.
- [17] Woo, P.; Humphries, S.E. IL-6 polymorphisms: a useful genetic tool for inflammation research?. *J Clin Invest* 2013, 123, 1413-1414. Doi:10.1172/JCI67221.
- [18] Shah, T.; Zabaneh, D.; Gaunt, T.; Swerdlow, D.I.; Shah, S.; Talmud, P.J.; Day, I.N.; Whittaker, J.; Holmes, M.V.; Sofat, R.; Humphries, S.E.; Kivimaki, M.; Kumari, M.; Hingorani, A.D.; Casas, J.P. Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. *Circ Cardiovasc Genet*, 2013, 6, 163-170. Doi: 10.1161/CIRCGENETICS.112.964254.
- [19] Cunningham, F.; Achuthan, P.; Akanni, W.; Allen, J.; Amode, M.R.; Armean, I.M.; Bennett, R.; Bhai, J.; Billis, K.; Boddu, S.; Cummins, C.; Davidson, C.; Dodiya, K.J.; Gall, A.; Girón, C.G.; Gil, L.; Grego, T.; Haggerty, L.; Haskell, E.; Hourlier, T.; Izuogu, O.G.; Janacek, S.H.; Juettemann, T.; Kay, M.; Laird, M.R.; Lavidas, I.; Liu, Z.; Loveland, J.E.; Marugán, J.C.; Maurel, T.; McMahon, A.C.; Moore, B.; Morales, J.; Mudge, J.M.; Nuhn, M.; Ogeh, D.; Parker, A.; Parton, A.; Patricio, M.; Abdul Salam, A.I.; Schmitt, B.M.; Schuilenburg, H.; Sheppard, D.; Sparrow, H.; Stapleton, E.; Szuba, M.; Taylor, K.; Threadgold, G.; Thormann, A.; Vullo, A.; Walts, B.; Winterbottom, A.; Zadissa, A.; Chakiachvili, M.; Frankish, A.; Hunt, S.E.; Kostadima, M.; Langridge, N.; Martin, F.J.; Muffato, M.; Perry, E.; Ruffier, M.; Staines, D.M.; Trevanion, S.J.; Aken, B.L.; Yates, A.D.; Zerbino, D.R., Flicek, P. Ensembl 2019. *Nucleic Acids Res* 2019, 47(D1), D745-D751.
- [20] 1000 Genomes Project Consortium; Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; Abecasis, G.R. A global reference for human genetic variation. *Nature* 2015, 526, 68-74. Doi: 10.1038/nature15393.
- [21] Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alföldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; Gauthier, L.D.; Brand, H.; Solomonson, M.; Watts, N.A.; Rhodes, D.; Singer-Berk, M.; England, E.M.; Seaby, E.G.; Kosmicki, J.A.; Walters, R.K.; Tashman, K.; Farjoun, Y.; Banks, E.; Poterba, T.; Wang, A.; Seed, C.; Whiffin, N.; Chong J.X.; Samocha, K.E.; Pierce-Hoffman, E.; Zappala, Z.; O'Donnell-Luria A.H., Minikel, E.V., Weisburd, B., Lek, M., Ware, J.S.; Vittal, C.; Armean, I.M.; Bergelson, L.; Cibulskis, K.; Connolly, K.M.; Covarrubias, M.; Donnelly, S.; Ferriera, S.; Gabriel, S.; Gentry, J.; Gupta, N.; Jeandet, T.; Kaplan, D.; Llanwarne, C.; Munshi, R.; Novod, S., Petrillo, N.; Roazen, D.; Ruano-Rubio, V.; Saltzman, A.; Schleicher, M.; Soto, J.; Tibbetts, K.; Tolonen, C.; Wade G.; Talkowski, M.E.; Genome Aggregation Database Consortium; Neale, B.M.; Daly, M.J.; MacArthur, D.G. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020, 581, 434-443. Doi: 10.1038/s41586-020-2308-7.
- [22] Knaus, B.J.; Grunwald, N.J. VCFR: A package to manipulate and visualize variant call format data in R. *Mol. Ecol. Resour* 2017, 17, 44-53. Doi: 10.1111/1755-0998.12549.
- [23] Ravasio, V.; Ritelli, M.; Legati, A.; Giacomuzzi, E. GARFIELD-NGS: Genomic variants filtering by deep learning models in NGS. *Bioinformatics* 2018, 34, 3038-3040. Doi: 10.1093/bioinformatics/bty303.
- [24] Laskowski, R.A., Stephenson, J.D.; Sillitoe, I.; Orengo, C.A.; Thornton, J.M. VarSite: Disease variants and protein structure. *Protein Sci* 2020, 29,111-119. Doi: 10.1002/pro.3746.
- [25] Desmet, F.O.; Hamroun, D.; Lalande, M.; Collod-Bérout, G.; Claustres, M.; Bérout, C. Human splicing finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res* 2009, 37, e67. Doi: 10.1093/nar/gkp215.
- [26] UniProt Consortium. UniProt: A worldwide hub of protein knowledge. *Nucleic Acids Res* 2019, 47, D506–D515. Doi: 10.1093/nar/gky1049.
- [27] Emilsson, V.; Ilkov, M.; Lamb, J.R.; Finkel, N.; Gudmundsson, E.F.; Pitts, R.; Hoover, H.; Gudmundsdottir, V.; Horman, S.R.; Aspelund, T.; Shu L.; Trifonov, V.; Sigurdsson, S.; Manolescu, A.; Zhu, J.; Olafsson, Ö.; Jakobsdottir, J.; Lesley, S.A.; To, J.;

Zhang, J.; Harris, T.B.; Launer, L.J., Zhang, B.; Eiriksdottir G.; Yang, X.; Orth, A.P.; Jennings, L.L.; Gudnason, V. Co-regulatory networks of human serum proteins link genetics to disease. *Science* 2018, 361, 769-773. Doi: 10.1126/science.aaq1327.

[28] Wang, Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol* 2020; 92, 568-576. Doi: 10.1002/jmv.25748.

[29] Akhmerov, A.; Marbán, E. COVID-19 and the Heart. *Circ Res* 2020, 126, 1443-1455. Doi:10.1161/CIRCRESAHA.120.317055.

[30] Zhang, C.; Shi, L.; Wang, F.S. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020, 5, 428-430. Doi:10.1016/S2468-1253(20)30057-1.

[31] Alqahtani, S.A.; Schattenberg, J.M. Liver injury in COVID-19: The current evidence. *United European Gastroenterol J* 2020, 8, 509-519. Doi:10.1177/2050640620924157.

[32] Li, Y.C., Bai, W.Z., Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020, 92, 552-555. Doi: 10.1002/jmv.25728.

[33] Helms, J.; Kremer, S.; Merdji, H; Clere-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; Anheim, M.; Meziani, F. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* 2020, 382, 2268-2270. Doi: 10.1056/NEJMc2008597.

[34] Zhang, C.; Wu, Z.; Li, J.W.; Zhao, H.; Wang, G.Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents* 2020, 55, 105954.

[35] Luo, P; Liu, Y; Qiu, L.; Liu, X.; Liu, D.; Li, J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol* 2020, 92, 814-818. Doi:10.1002/jmv.25801.

## Figures




Figure 1

Canonical pathways involving IL6 and IL6R retrieved by IPA software. This figure has been created by "Path Designer" IPA tool.





Figure 2

Workflow of the analytical steps performed in the study. CNV: Copy Number Variation; SNV: Single Nucleotide Variants; HSF: Human Splicing Finder; IPA: Ingenuity Pathway Analysis.



**Figure 3**

Pathophysiological conditions in which IL6 and IL6R may be implicated following the “Disease & Functions” analysis performed on IPA tool. The figure has been created by “Path Designer” IPA tool.